The purpose of this study was to assess the usefulness of sentinel node biopsy (SNB) after neoadjuvant chemotherapy (NAC) in patients with clinically node-negative breast cancer. SNB after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB. Background: Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC. Patients and Methods: At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013. The clinicopathological and survival data of patients who underwent SNB after NAC (the NAC group) and those who underwent SNB without NAC (the control group) were compared. Patients with a metastatic sentinel node underwent axillary lymph node dissection. Results: The number of patients in the NAC and control groups was 183 (15.5%) and 996 (84.5%), respectively. At diagnosis, tumors were significantly larger in the NAC group (P < .0001). Sentinel nodes were identified in almost all patients in both groups (99.5% in the NAC group vs. 99.8% in the control group). They were nonmetastatic in 147 (80.8%) patients in the NAC group and 849 (85.5%) patients in the control group. At the median follow-up time of 51.1 months, 6 patients (0.6%) in the control group had axillary lymph node recurrence compared with no patients in the NAC group. Conclusion: SNB after NAC was as accurate as SNB without NAC in patients with clinically node-negative breast cancer. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.
Introduction
Sentinel node biopsy (SNB) has replaced axillary lymph node dissection (ALND) as the standard method for axilla staging. SNB avoids the complications associated with ALND and allows reliable assessment of nodal status in patients with clinically node-negative breast cancer. [1] [2] [3] Initially used to convert locally advanced breast cancers from inoperable to operable, [4] [5] [6] neoadjuvant chemotherapy (NAC) is now used to downstage tumors for breast-conserving surgery 7, 8 and improve cosmesis. In addition, it is used to assess the in vivo chemosensitivity and biology of breast tumors and the long-term outcomes of breast cancer patients on the basis of tumor responses. 9 Because of these advantages, clinicians have administered NAC to patients with clinically node-negative disease with increasing frequency. Whether SNB should be performed after NAC is controversial 10, 11 and has been the subject of several prospective randomized trials. [12] [13] [14] A meta-analysis and some clinical trials showed that SNB after NAC was as feasible and accurate as SNB without NAC in clinically node-negative patients at presentation. [15] [16] [17] [18] [19] [20] [21] [22] In almost all trials, ALND was performed to evaluate false-negative rates when sentinel nodes were negative for metastasis; therefore, long-term follow-up data regarding axillary recurrence after SNB without ALND are limited. 21, 23 To assess the usefulness of SNB after NAC,
we compared axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC.
Patients and Methods

Patients
At our hospital, 1179 consecutive women with a clinically node-negative axilla at presentation and T0 to T3 breast cancer underwent SNB from April 2007 to December 2013. A clinically node-negative axilla was defined as the absence of palpable disease in the nodal basin and, when assessed, the absence of abnormally appearing lymph nodes on ultrasound, magnetic resonance imaging, or computed tomography images. When lymph nodes had a suspected cancerous appearance on images, negativity was confirmed via fine needle aspiration. Clinicopathological and survival data were compared between patients who underwent SNB after NAC and those who underwent SNB without NAC. This study was approved by the ethics committee of the Jikei University School of Medicine, and patient consent was obtained.
Surgical Intervention and Nodal Evaluation
Sentinel node biopsy was performed using a radiocolloid and a dye. Mapping agents were injected into the subdermal plexus. 99m T C -labeled phytate colloid was injected on the day of surgery (0.25 mL, 15 MBq) or the day before surgery (0.5 mL, 30 MBq), and lymphoscintigraphy was performed. During the surgery, 5 mL of isosulfan blue dye (Lymphazurin; Covidien, Mansfield, MA) or 3 mL of indocyanine green dye (Diagnogreen; Daiichi Sankyo, Tokyo, Japan) was injected. The sentinel nodes were identified as those with dye uptake, radiotracer uptake, or both.
All sentinel nodes were sectioned along their short axis at 2-mm intervals. The nodal tissue was quickly frozen in liquid nitrogen, and a single 5-mm thick section stained with hematoxylin and eosin (H & E) was examined intraoperatively (frozen-section analysis). If a section was metastatic, complete ALND was performed immediately. Sentinel nodes with metastases larger than 0.2 mm were considered to be positive; isolated tumor cells were considered to be negative. Nonsentinel lymph nodes were examined via singlesection H & E staining. The following parameters were evaluated in all primary tumors: size of the invasive component, histological type, nuclear grade, estrogen and progesterone receptor status, HER2 status, and the presence of lymphovascular invasion. The hormonal status was considered to be positive if 10% of the invasive cells were immunohistochemically stained. According to the Hercep-Test criteria, 24 a staining score of 3þ was considered to be positive; a 2þ score was considered to be positive only when confirmed via fluorescence in situ hybridization with an amplification ratio of 2.0. Most patients who received conservative surgery also received whole breast radiotherapy; patients with more than 4 positive nodes received regional lymph node radiotherapy. Patients who underwent a mastectomy may or may not have undergone locoregional radiotherapy. Systemic and breast examinations were performed before NAC, before surgery, and every 12 months postoperatively and comprised computed tomography of the chest and abdomen, magnetic resonance imaging of the brain, a bone scan, mammograms, and breast ultrasound imaging.
Statistical Analysis
Patients were divided into 2 groups for statistical analysis: those who underwent SNB after NAC and those who underwent SNB without NAC. Clinicopathological data were tabulated for each group. The primary end point for statistical analysis was the axillary recurrence-free survival (ARFS). The secondary end points were overall and distant disease-free survival. The KaplaneMeier method was used to generate survival curves and the cumulative incidence of events. Survival was calculated from the date of surgery to the date of the event or latest follow-up. The log-rank test was used to assess differences in the KaplaneMeier curves. We examined the success rate for identifying and removing a sentinel node. The Fisher exact test was used to evaluate the comparisons of the clinicopathological data and success rates between the 2 groups. All P values were 2-tailed, and P values .05 were considered to be significant. All analyses were performed using Stata statistical software (StataSE 10; StataCorp LP, College Station, TX).
Results
Patients and Tumor Characteristics
The study population comprised 1179 patients with clinically node-negative breast cancer between April 2007 and December 2013. All patients underwent SNB as part of their surgical treatment. Among the 1179 patients, 183 patients (15.5%) underwent SNB after NAC (the NAC group) and 996 patients (84.5%) underwent SNB without NAC (the control group). No patient had disease progression while undergoing NAC.
The demographic, clinical, and pathological characteristics of the patients are summarized in Table 1 . Patients in the NAC group had larger tumors (P < .0001) at diagnosis than those in the control group. Estrogen receptor expression (66.6% vs. 83.9%; P < .0001) and progesterone receptor expression (47.0% vs. 73.7%; P < .0001) were significantly lower in the NAC group than in the control group. No significant difference was observed in age, HER2
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Results of the SNB
The results of the SNB are presented in Table 2 . A sentinel node was identified in 1175 patients (99.7%). The identification rate was 99.5% in the NAC group and 99.8% in the control group; this difference was not significant. The numbers of excisional and metastatic sentinel nodes and other parameters did not significantly differ between the 2 groups (Table 3) . Furthermore, 147 patients (80.8%) in the NAC group and 849 patients (85.5%) in the control group had negative sentinel nodes and did not undergo ALND.
Positive Rate of the Axillary Nodes
The overall rate of positive sentinel nodes was 19.1% in the NAC group and 14.2% in the control group. When analyzed according to T stage at presentation, sentinel node positivity was lower in the NAC group than in the control group (T0/1: 4.2% vs. 8 Figure 1 . No significant difference was observed in axillary recurrence between the 2 groups (log-rank P ¼ .28).
Other unfavorable events occurred in 9 patients in the NAC group and 25 patients in the control group. The number of patients with other regional node failure, ipsilateral breast cancer, and distant metastasis was 1 (0.5%), 2 (1.1%), and 6 (3.3%) in the NAC group and 1 (0.1%), 6 (0.6%), and 18 (1.8%) in the control group, respectively. Five-year distant disease-free survival was 96.1% (95% CI, 91.4-98.2) in the NAC group, and 97.5% (95% CI, 95.9-98.5) in the control group. Overall, 10 women died during follow-up; 2 in the NAC group (5-year overall survival [OS], 99.3%; 95% CI, 95.3-99.9) and 8 in the control group (5-year OS, 98.9%; 95% CI, 97.8-99.5). Death was attributed to breast cancer in 100% in the NAC group and 63% in the control group. Distant disease-free and OS were not significantly different between the NAC group and the control group (log rank P ¼ .19 and P ¼ .77).
Discussion
Axillary lymph node status is an important prognostic factor in breast cancer and guides regional and systemic treatment decisions (eg, whether to administer radiotherapy and/or chemotherapy). Surgical removal of axillary lymph node metastases best protects against recurrence in the axillary nodal basin; however, surgical removal via ALND (compared with no removal) had no survival benefits in clinical trials of patients with early-stage breast cancer. 25 Furthermore, ALND is associated with lymphedema of the arm, pain, paresthesia, and restriction of the shoulder girdle. 26, 27 To avoid such complications, SNB is now widely used for nodal staging in patients with clinically node-negative breast cancer.
1-3
Neoadjuvant chemotherapy is a widely accepted treatment for breast cancer that has proved to be as effective as adjuvant therapy. As advantages, NAC enables in vivo determination of tumor chemosensitivity, reduces the incidence of micrometastases, and reduces disease burden to allow less extensive surgery. 28 In 2005, the original American Society of Clinical Oncology (ASCO) guidelines for the use of SNB in early-stage breast cancer cited a meta-analysis in which the sentinel node identification rate 
Sentinel Node Biopsy After Neoadjuvant Chemotherapy
for SNB was 96%, with a false-negative rate of 7.3%. 4 However, performance of SNB after NAC has been highly controversial, and complete ALND has been the standard treatment for patients who undergo NAC, regardless of the clinical status of the axilla. Sentinel node biopsy produces false-negative results when it fails to detect cancer in the sentinel nodes, as confirmed via ALND. Several reports have shown a higher false-negative rate in patients who underwent SNB after NAC than in those who underwent SNB without NAC. Because of fibrosis of the lymphatic channels and occlusion of the lymph nodes with cellular debris, tumor eradication using NAC reduces axillary lymphatic drainage, which can impede the identification of the sentinel nodes. The effects of chemotherapy on the lymph nodes might not be uniform, and residual disease might persist in the nonsentinel nodes after disease regression in the sentinel nodes; consequently, SNB might be an unreliable detector of metastatic nodes in parts of the axilla when performed after NAC. 29, 30 Furthermore, a retrospective analysis in a large multicenter series and a recent meta-analysis have shown similar sentinel node identification rates and false-negative rates in clinically node-negative breast cancer patients who underwent SNB without NAC versus SNB after NAC. In the meta-analysis, the false-negative rates for SNB after NAC in patients with clinical N0 (cN0) disease ranged from 9.4% to 12%. [15] [16] [17] [18] [19] [20] [21] [22] The National Surgical Adjuvant Breast and Bowel Project B-27 trial, which included cN0 as well as clinical N1 (cN1) disease, reported a false-negative rate of 10.7% for SNB after NAC. 31 The updated 2014 ASCO guidelines cited "intermediatelevel evidence" that the advantages of SNB after NAC outweigh the disadvantages. The guidelines did not recommend the use of SNB after NAC in patients with cN1 or clinical N2 disease because several prospective clinical trials showed false-negative rates of 10% to 30%, [14] [15] [16] 32, 33 which were considered to be unacceptably high.
Sentinel node identification rates after NAC in patients with cN0 disease ranged from 85% to 97.4% in a previous meta-analysis and in recent reports. [15] [16] [17] [18] [19] [20] [21] [22] In our study, the identification rates were as high in patients who underwent SNB after NAC as in those who underwent SNB without NAC. We set strict criteria for patient selection, including the absence of palpable disease in the nodal basin as well as the absence of abnormal or nodes suspected to be cancerous on axillary ultrasound, computed tomography, or magnetic resonance images. Axillary nodes that appeared metastatic on ultrasound images were reassessed via fine needle aspiration, and patients with confirmed metastatic nodes before NAC were not considered as candidates for SNB after NAC. Furthermore, we used 2 mapping agents (radiocolloid and dye), which reduces the likelihood of false-negative rates and increases identification rates. [13] [14] [15] 20, 22 In our study, the identification rate in the NAC group was higher when both mapping agents were used compared with the cases when either of the mapping agents was used (both, 99.5%; radiocolloid, 95.6%; dye, 78.5%). We did not determine the false-negative rate in our study. A higher false-negative rate in the NAC group would have resulted in undetected nodal metastases and a higher axillary recurrence rate. Importantly, although ALND was not performed in sentinel node-negative patients, no axillary node recurrence was observed in the NAC group during the median follow-up period of more than 4 years. Whether SNB should be performed before or after NAC has been a topic of discussion. In support of the former, some surgeons prefer to know the pretreatment tumor size and lymph node status for chemotherapy treatment planning and to predict prognosis. Alternatively, the higher incidence of a complete pathological response in patients undergoing NAC via novel targeted therapies enables surgeons to perform more conservative axillary surgical procedures. SNB after NAC also obviates the need for ALND in patients with a clinically occult axilla if the nodal metastases are eradicated by chemotherapy. NAC has been shown to eliminate up to 40% of the nodal disease. 34, 35 In our study, patients in the NAC group with T1 to T3 disease at presentation had a lower requirement for ALND than their counterparts in the control group; this apparently reflects the lower incidence of positive sentinel nodes in the NAC group. In previous studies in which SNB was performed before NAC, the nodepositive rate was as high as 40% in patients with T2 disease and as high as 70% in patients with T3 disease. 36, 37 Because of better clinical and pathologic response rates, ALND can be avoided in more than 50% of patients with clinically node-negative disease. 35, 38 Several studies have suggested that post-NAC staging more meaningfully predicts locoregional recurrence than pre-NAC staging and is a prognostic indicator. 39, 40 As another advantage, post-NAC SNB requires a single surgical procedure with potentially fewer axillary dissections, whereas pre-NAC SNB requires 2 surgical procedures. Moreover, SNB after NAC reduced the need for complete ALND. 
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Conclusion
Sentinel node biopsy after NAC was as accurate as SNB without NAC in patients with clinically node-negative breast cancer. Although the follow-up times were short, ARFS rates were excellent.
Clinical Practice Points
In this study we assessed the usefulness SNB after NAC in the patients with clinically node-negative breast cancer. Sentinel node biopsy after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent. 
